Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.

MLA

Erem, Cihangir, et al. “Increased Thrombin-Activatable Fibrinolysis Inhibitor and Decreased Tissue Factor Pathway Inhibitor in Patients with Hyperthyroidism.” Endocrine, vol. 36, no. 3, Dec. 2009, pp. 473–78. EBSCOhost, https://doi.org/10.1007/s12020-009-9271-2.

APA

Erem, C., Ucuncu, O., Yilmaz, M., Kocak, M., Nuhoglu, İ., & Ersoz, H. O. (2009). Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism. Endocrine, 36(3), 473–478. https://doi.org/10.1007/s12020-009-9271-2

Chicago

Erem, Cihangir, Ozge Ucuncu, Mustafa Yilmaz, Mustafa Kocak, İrfan Nuhoglu, and Halil Onder Ersoz. 2009. “Increased Thrombin-Activatable Fibrinolysis Inhibitor and Decreased Tissue Factor Pathway Inhibitor in Patients with Hyperthyroidism.” Endocrine 36 (3): 473–78. doi:10.1007/s12020-009-9271-2.